Abstract

The tumour microenvironment (TME) presents a major block to anti-tumour immune responses and to effective cancer immunotherapy. The inflammatory mediators such as cytokines, chemokines, growth factors and prostaglandins generated in the TME alter the phenotype and function of dendritic cells (DCs) that are critical for a successful adaptive immune response against the growing tumour. In this mini review we discuss how tumour cells and the surrounding stroma modulate DC maturation and trafficking to impact T cell function. Fibroblastic stroma and the associated extracellular matrix around tumours can also provide physical restrictions to infiltrating DCs and other leukocytes. We discuss interactions between the inflammatory TME and infiltrating immune cell function, exploring how the inflammatory TME affects generation of T cell-driven anti-tumour immunity. We discuss the open question of the relative importance of antigen-presentation site; locally within the TME versus tumour-draining lymph nodes. Addressing these questions will potentially increase immune surveillance and enhance anti-tumour immunity.

Highlights

  • Anti-tumour immunity is the ability of the body’s immune system to recognise and eliminate tumour cells

  • It is established that tumours can exploit their surroundings to create an immunosuppressive microenvironment to control dendritic cells (DCs) function within both the tumour microenvironment (TME) and Tumour draining lymph node (TDLN) [178, 179]

  • The success of immunotherapy relies on enhanced T cell activity, activation of tumour-specific T cells cannot be achieved without prior antigen presentation by professional DCs

Read more

Summary

Control of Dendritic Cell Function Within the Tumour Microenvironment

Stromal Immunology Laboratory, MRC Laboratory for Molecular Cell Biology, University College London, London, United Kingdom. Specialty section: This article was submitted to Molecular Innate Immunity, a section of the journal

Frontiers in Immunology
INTRODUCTION
DC Maturation and DC Gene Signatures in Tumours
TME FACTORS AFFECTING DC DEVELOPMENT IN TUMOURS
IMMUNE CHECKPOINT GENES
LEVERAGING DC BIOLOGY IN CANCER THERAPIES
DISCUSSION

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.